Helix Biopharm (HBP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 07/31
| 04-2023 | 01-2023 | 10-2022 | 07-2022 | 04-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,330 | 2,824 | 4,397 | 3,252 | 1,882 |
| Receivables | 114 | 105 | 149 | 280 | 349 |
| Other current assets | 0 | 0 | -38 | -1 | 0 |
| TOTAL | $1,551 | $3,158 | $4,762 | $3,695 | $2,297 |
| Non-Current Assets | |||||
| PPE Net | 36 | 39 | 38 | 35 | 37 |
| Other Non-Current Assets | 0 | 0 | 1 | 0 | 0 |
| TOTAL | $36 | $39 | $39 | $35 | $37 |
| Total Assets | $1,587 | $3,197 | $4,801 | $3,730 | $2,335 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | 2,468 | 1,935 |
| Accounts payable and accrued liabilities | 391 | 707 | 660 | 599 | 927 |
| Accrued Expenses | 283 | 266 | 377 | 345 | 450 |
| Other current liabilities | N/A | N/A | 4,629 | -1 | N/A |
| TOTAL | $674 | $973 | $5,666 | $3,411 | $3,312 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | N/A | 947 |
| TOTAL | $0 | $0 | $0 | $0 | $947 |
| Total Liabilities | $674 | $973 | $5,666 | $3,411 | $4,259 |
| Shareholders' Equity | |||||
| Common Shares | 152,068 | 152,068 | 147,916 | 147,511 | 143,916 |
| Retained earnings | -199,254 | -197,908 | -196,723 | -195,117 | -193,731 |
| Other shareholders' equity | 6,312 | 7,904 | 9,379 | 10,335 | 17,898 |
| TOTAL | $913 | $2,224 | $-865 | $319 | $-1,924 |
| Total Liabilities And Equity | $1,587 | $3,197 | $4,801 | $3,730 | $2,335 |